Prosecution Insights
Last updated: November 20, 2026
Application No. 18/548,657

SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS

Non-Final OA §112
Filed
Sep 01, 2023
Priority
Mar 03, 2021 — provisional 63/200,366 +1 more
Examiner
WHITE, DAWANNA SHAR-DAY
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Curators of the University of Missouri
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
82 granted / 130 resolved
+3.1% vs TC avg
Strong +21% interview lift
Without
With
+21.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
203
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
13.9%
-26.1% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 130 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . All previous objections and rejections not reiterated herein were overcome by claim amendments, filed October 9th, 2026, have been fully considered and found persuasive. As such all objections and rejections not reiterated herein have been withdrawn. Election/Restrictions Claims 1 – 2, and 5 – 7, are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 8 – 19, and 21 – 22, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on December 4th, 2025 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8 – 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites the limitation "the pharmaceutical compound" in line 4; however, claim 7, from which claim 8 depends, does not recite a limitation for a “pharmaceutical compound.” Moreover, independent claim 1, from which claim 7 depends, does not recite a limitation for a “pharmaceutical compound” either. Thus, there is insufficient antecedent basis for this limitation in the claim. Moreover, claims 9 – 19 are included in the rejection since the claims dependent from claim 8 but do not address the deficiency. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 14 – 19 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 14 recites, the method of claim 13, wherein a therapeutically effective amount is an amount that prevents entry of a SARS-CoV-1 or SARS-CoV-2 virus mediated by a spike protein of the SARS-CoV-1 or SARS-CoV-2 virus into a cell of the mammal. However, claim 10, in the chain of dependency, recites the method of claim 9 where the mammal is human. Therefore, by reciting the broad genus of mammal in claim 14, claim 14 fails to further limit the mammal and instead broadens the scope of the claim to encompass all mammals not just humans. Moreover, claims 15 – 19 are included in the rejection since the claims dependent from claim 14 but do not address the deficiency. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Discussion of the Prior Art Claims 1 – 2, and 5 – 6 direct to a compound having one of the following formulae where R10 – 18, Y1, L, and M are defined. Moreover, claim 7 directs to a pharmaceutical composition, comprising: the compound of claim 1; and a pharmaceutically acceptable carrier. Furthermore, claims 21 – 22 direct to method of treating a SARS-CoV-2 virus infection in a subject, comprising administering the compound of claim 1, or a pharmaceutically acceptable salt thereof, to the subject, wherein the compound binds to SARS-CoV-2 S-RBD/ACE-2 Complex but does not bind to S-RBD alone or ACE-2 alone. The closet prior art of Spain Patent Application ES 518427 A1 to Saleta et. al. (Saleta’427; cited IDS dated April 14th, 2025) teach compound 13 of the structure PNG media_image1.png 200 400 media_image1.png Greyscale that was prepared from recrystallization from ethyl acetate. See page 3 Table III Entry 13 and page 5 line 1. Moreover, Saleta’427 teach compounds of this disclosure as potential therapeutics. See page 2 lines 1 – 3. However, Saleta’427 fails to teach any of the compounds as recite in claim 1 of formulae (Ia), (IIb), (IIc), (IId), (IIe), or (III). See claim 1 limitation. Moreover, the prior art fails to provide motivation to modify the structure of compound 13 to specifically modify the position of the S atom to have either an O or N atom, modify the N-H to make an N-CH3 bond, add the additional heteroatom of N to the ring system, and/ or replace the 7 or 8 membered ring in the center for a chain group. Thus, the prior art of Saleta’427 fails to anticipate or render obvious the compound species of claims 1 – 2, and 5 – 7. Therefore, claims 1 – 2, and 5 – 7 are free of the prior art. Moreover, claims 21 – 22 which direct to a method of treating a SARS-CoV-2 virus infection comprising administering the compound of claim 1 is also free of the prior art. Conclusion Claims 8 – 19 are rejected. Claims 1 – 2, 5 – 7, and 21 – 22 are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAWANNA S WHITE whose telephone number is (703)756-4687. The examiner can normally be reached 7:00 am - 5:00 pm [EST] M - Th. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAWANNA SHAR-DAY WHITE/Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Show 1 earlier event
Mar 09, 2026
Non-Final Rejection mailed — §112
May 28, 2026
Response Filed
Jun 11, 2026
Final Rejection mailed — §112
Jul 23, 2026
Interview Requested
Aug 04, 2026
Examiner Interview Summary
Oct 09, 2026
Request for Continued Examination
Oct 13, 2026
Response after Non-Final Action
Nov 12, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790323
CDK19-Selective Inhibitors, and Methods of Use Thereof
3y 9m to grant Granted Nov 10, 2026
Patent 12780807
NOVEL DIPHENAZINE COMPOUND, AND USE THEREOF FOR PREVENTING OR TREATING CANCER OR NEUROINFLAMMATORY DISEASES
2y 11m to grant Granted Nov 03, 2026
Patent 12758553
USE OF POZIOTINIB FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
4y 2m to grant Granted Oct 13, 2026
Patent 12753161
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE
4y 0m to grant Granted Oct 06, 2026
Patent 12753163
DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1
3y 5m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
84%
With Interview (+21.1%)
3y 5m (~3m remaining)
Median Time to Grant
High
PTA Risk
Based on 130 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month